Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Non-Small Cell Lung Cancer and Pleural Mesothelioma

In brief

This is an open-label, two-arm, multicenter Phase IA/II dose-escalation study of PTK787 in combination with Pemetrexed alone (Cohort 1) or Pemetrexed and Cisplatin (Cohort 2). This study is designed to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of PTK787 when administered in combination with Pemetrexed or Pemetrexed and Cisplatin, and to characterize the safety, tolerability, biologic activity, and PK profile of PTK787 in adult patients with advanced non-small cell lung cancers and mesotheliomas.

Key facts

Study ID

NCT00281125

Run by

Nevada Cancer Institute

People needed

20

Starts

2006-01-01

Expected to finish

2008-08-01

Last updated by the study team

2012-03-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with advanced non-small cell lung cancers (non-squamous variety and advanced mesotheliomas
• Patients with advanced solid tumors who are refractory to standard treatments and/or standard treatments are not be available for the patient

You may not qualify if…

• Non-small cell carcinoma of squamous variety
• Patients with uncontrolled brain metastases

Where it is running

• Nevada Cancer Institute — Las Vegas, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.